Specialized Dermatological - Rheumatological Patient Management Improves Diagnostic Outcome and Patient Journey: A Four-Year Analysis

Jana Ziob (✉ Jana.Ziob@ukbonn.de)  
University Hospital of Bonn

Charlotte Behning  
University Hospital of Bonn

Peter Brossart  
University Hospital of Bonn

Thomas Bieber  
University Hospital of Bonn

Dagmar Wilsmann-Theis  
University Hospital of Bonn

Valentin Sebastian Schäfer  
University Hospital of Bonn

Research Article

Keywords: dermatological-rheumatological patient management, psoriasis, psoriatic arthritis, patient journey, diagnostic outcome

DOI: https://doi.org/10.21203/rs.3.rs-425000/v1

License: ☑️ ☐️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background:

Management of psoriatic arthritis (PsA) and other rheumatological diseases requires an interdisciplinary approach involving dermatologists and rheumatologists. The aim of the study was to analyze the specialized dermatological-rheumatological management before and after foundation of a PsA center.

Methods:

A retrospective cohort study of all dermatology-rheumatology consultations during two periods was conducted. Period one, from April 1st, 2016 to February 28th, 2018 versus period two, from March 1st, 2018 to January 31st, 2020, after foundation of a PsA center. Clinical data on patient characteristics including psoriasis subtypes, clinical symptoms and signs, disease activity scores, classification criteria and comorbidities as well as patient journey were extracted and analyzed.

Results:

404 consultations were studied. Close collaboration in a PsA center lead to a relevantly shortened patient journey concerning rheumatological complaints: period 1: median (IQR): 36.0 (10.0-126.0) months, period 2: median (IQR): 24.0 (6.0-60.0) months. Established scores and classification criteria such as GEPARD or CASPAR did not assist in diagnosis of PsA. Arthralgia (p=0.0407), swollen joints (p=0.0151), morning stiffness (p=0.0451) and dactylitis (p=0.0086) helped to distinguish between osteoarthritis and PsA.

Conclusions:

Clinical signs and symptoms, scores and classification criteria usually assessed were less helpful than expected in diagnosis of PsA and other rheumatological diseases. Close collaboration in a specialized PsA center yielded the fastest way of diagnosis.

Background

Psoriasis is a common chronic inflammatory immune-mediated skin disorder which affects about 2–3% of adults in Western populations and therefore has a substantial socio-economic significance (1). Psoriatic Arthritis (PsA), which occurs in up to 40% of patients affects peripheral joints, the spine, and tendons (2–4). It is estimated that 29% of psoriasis patients seen by dermatologists suffer from undiagnosed PsA (5). This can be due to dermatologists primarily concentrating on skin lesions, rather than joint complaints (3). In most cases, psoriasis develops 10–12 years before the occurrence of PsA, underlining the important role of dermatologists in recognizing joint disorders for timely referral and adequate therapy (3, 6, 7). Alternatively, in 14–20% of PsA patients, arthritis can occur before or simultaneously with psoriasis (8). The overlap between dermatologists and rheumatologists is greater than psoriasis and PsA, as well as connective tissue diseases or vasculitis. In patients with systemic lupus erythematosus, the skin is the second most commonly involved organ, after arthritis, affecting up
to 30% of patients (9). Furthermore, patients complain commonly about rheumatological symptoms like arthralgia, which might be hard to differentiate for the dermatologist.

Despite the assumed high importance of interdisciplinary collaboration in dermatology-rheumatology, the clear evidence for it has not been explored significantly yet. Therefore, we designed a study at our University Hospital Bonn to compare two specific periods, one before and one after the foundation of a specialized PsA center, enabling close dermatology-rheumatology cooperation. This is the first study focusing on the role of early dermatology-rheumatology management for diagnosis and therapy of PsA and other rheumatic diseases considering the patient journey in order to reduce the time for diagnosis in a specialized center setting.

**Methods**

**Study design and participants:**

We performed a retrospective cohort study of the interdisciplinary dermatology-rheumatology cooperation and management focusing on PsA, other rheumatic diseases and non-rheumatic diseases by comparing two specific periods: period 1, from April 1st, 2016 to February 28th, 2018 versus period 2, March 1st, 2018 to January 31st, 2020, after foundation of a specialized PsA center. Once a week a consultation shared by dermatologist and rheumatologist took place in the department of rheumatology, with examination of dermatological patients suspected of suffering from rheumatological diseases.

**Data collection:**

Detailed clinical data was obtained from Dedalus ORBIS™, which is used as main electronic health record system at the University Hospital Bonn. We analyzed all consultation records between both departments. The study followed the principles of the Declaration of Helsinki and the guidelines of Good Clinical Practice and was approved by the local ethics committee of the University Hospital Bonn (Ethik-Kommission der Medizinischen Fakultät Bonn – Lfd. Nr. 100/20). Due to the retrospective design of the study, the need for informed consent was waived by the ethics committee of the University Hospital of Bonn, Germany, (Chairman Prof. Dr. Racké).

General characteristics collected during the study included patient’s age, sex, body mass index, comorbidities, history of smoking and laboratory parameters such as rheumatoid factor, anti-CCP antibodies, C-reactive protein and more. Furthermore, we assessed subtype of psoriasis, family history, nail, scalp and rima ani involvement. We also included the following established disease scores: PASI (Psoriasis Area and Severity Index), DLQI (Dermatology Life Quality Index), GEPARD (German Psoriatic Arthritis Diagnostic Questionnaire) and CASPAR (Classification Criteria for Psoriatic Arthritis). Other collected data included duration of skin lesions and rheumatological complaints, suspected diagnosis and duration from consult request until consultation. We also assessed all pre-diagnosed and first diagnosed diseases, clinical signs and symptoms and fulfillment of classification criteria. CASPAR
classification criteria were applied for PsA and respective classification criteria for other rheumatological
diseases, if available for the diagnosis.

**Statistical analysis:**

Exploratory data analysis was performed with “R”, version 4.0.2 (10). Categorical variables were
expressed as absolute and relative frequencies, continuous variables in mean ± standard deviation (SD)
and median + interquartile range (IQR). Categorical variables were examined using Chi-Square test or
Fisher's exact test, when absolute frequencies were below five. Continuous variables were compared by
using Wilcoxon tests when normality could not be assumed. Descriptive statistics are presented, as p <
0.05 was considered significant. For some parameters subgroup analyses were performed based on the
presence of psoriasis, PsA, other rheumatological diseases or non-rheumatological diseases including
osteoarthritis (OA).

**Results**

Over the four-year period, 404 dermatological consultations were answered by the department of
rheumatology. 61 out of 587 rheumatological consultations were addressed in the first period and 343
out of 1104 rheumatological consultations in the second period. Excluding follow-up consultations, 373
patients including 165 men and 208 women with a mean age of 52.3 (± 15.4) years were studied.
Coexisting diseases were counted separately.

**Patient characteristics:**
### Table 1
Patient characteristics in patients with psoriasis, PsA, other rheumatological diseases and non-rheumatological diseases over both periods

| Parameter                        | Psoriasis | Psoriatic arthritis | Other rheumatological diseases | Non-rheumatological diseases |
|----------------------------------|-----------|---------------------|--------------------------------|-----------------------------|
| Number, n in total               | 218       | 103                 | 43                             | 67                          |
| Age (years) (mean ± SD)          | 49.9 ± 14.70 | 52.0 ± 13.90        | 53.7 ± 17.70                   | 59.6 ± 14.30                |
| Gender: men, n (%)               | 115 (52.75) | 56 (54.37)          | 15 (34.88)                     | 20 (29.85)                  |
| Gender: woTmen, n (%)            | 103 (47.25) | 47 (45.63)          | 28 (65.12)                     | 47 (70.15)                  |
| BMI (kg/m²) (mean ± SD)          | 29.1 ± 6.50 | 29.4 ± 6.40         | 25.8 ± 6.90                    | 30.9 ± 8.80                 |
| Elevated CRP-Level (≥ 5 mg/l), n (%) | 44 (20.18) | 20 (19.42)          | 20 (46.51)                     | 17 (25.37)                  |
| Elevated anti-CCP antibodies (≥ 8.0 U/ml), n (%) | 6 (2.75) | 3 (2.91)            | 8 (18.60)                      | 3 (4.48)                    |
| Elevated RF-Level (≥ 14 IU/ml), n (%) | 13 (5.96) | 6 (5.83)            | 12 (27.91)                     | 0 (0)                       |
| Smoking, ever, n (%)             | 102 (46.79) | 41 (39.81)          | 13 (30.23)                     | 23 (34.33)                  |
| Smoking, never, n (%)            | 60 (27.52) | 31 (30.10)          | 12 (27.91)                     | 18 (28.36)                  |
| Allergies, n (%)                 | 80 (36.70) | 32 (31.07)          | 17 (39.53)                     | 27 (41.79)                  |
| Initial diagnosis, n             | -         | 43                  | 26                             | 56                          |

Abbreviations: n: number, BMI: body mass index, CRP: C-reactive protein, anti-CCP antibody: anti-cyclic citrullinated peptide antibody, RF: rheumatoid factor

Analysis of our whole cohort confirmed the presence of psoriasis in 218 of 373 patients, while PsA was diagnosed in 103 cases (47.25%). Thirty-nine patients with PsA (37.86%) had a positive family history of psoriasis. Body mass index (BMI) and gender distribution did not differ between these two groups. The lowest BMI was observed in patients with other rheumatological diseases. The highest prevalence in history of smoking was present in patients with psoriasis (46.79%), followed by PsA patients (39.81%) (Table 1).

**Disease activity scores and classification criteria:**
Table 2
- Disease activity scores and classification criteria in patients with psoriasis and psoriatic arthritis at the time of consultation

| Element / Disease                  | Psoriasis patients | Psoriatic arthritis patients |
|-----------------------------------|--------------------|------------------------------|
| Number, n in total                | 218                | 103                          |
| PASI (mean ± SD)                  | 12.1 (± 8.4)       | 11.8 (± 9.6)                 |
| DLQI (mean ± SD)                  | 14.5 (± 6.8)       | 15.9 (± 6.8)                 |
| GEPARD (mean ± SD)                | 6.7 (± 3.3)        | 8.2 (± 2.7)                  |
| CASPAR (mean ± SD)                | 5.1 (± 1.8)        | 5.8 (± 1.7)                  |

Abbreviations: n: number, PASI: psoriasis Area and Severity Index, DLQI: dermatology life quality index, GEPARD: German psoriatic arthritis diagnostic questionnaire, CASPAR: classification criteria for psoriatic arthritis

Comparison of both the periods revealed diagnosis of PsA in 103 patients with psoriasis, while the initial diagnosis confirmed it in only 43 patients. Clinical signs and symptoms were assessed anamnestically. In the PsA group, all patients reported of arthralgia, while 56 patients (54%) reported of previously swollen joints and 26 (24%) of tender joints. 29 patients (28%) reported morning stiffness lasting over 60 minutes. In Psoriasis group, 210 patients (96%) suffered from arthralgia, 92 (42%) reported of previously swollen joints and 48 (22%) from previously tender joints (Table 2). Suspected PsA was confirmed in 78 cases out of 277 patients (28.16%).

**Psoriasis subtypes:**

Table 3
Psoriasis subtypes in patients with psoriatic arthritis

| Psoriasis forms                          | n (%)  |
|-----------------------------------------|--------|
| in total                                 | 103 (100) |
| Isolated plaque psoriasis               | 89 (86.41) |
| Isolated pustular psoriasis             | 8 (7.77) |
| Isolated inverse psoriasis              | 1 (0.97) |
| Isolated scalp psoriasis                | 4 (3.88) |
| Isolated nail psoriasis                 | 1 (0.97) |
| Concomitant involvement of the scalp    | 51 (49.51) |
| Concomitant involvement of the rima ani | 50 (48.54) |
| Concomitant involvement of the nails    | 44 (42.72) |

Abbreviations: n: number
The most prevalent type of psoriasis in patients with PsA was plaque psoriasis reported in up to 86.4% of patients. Concomitant nail, scalp and rima ani involvement was observed with similar frequencies in psoriasis and PsA groups (Table 3). Of all measurements of PsA patients (103), 69 patients (66.99%) reported suffering from skin manifestations before joint complaints appeared, 7 patients (6.80%) stated joint complaints before developing psoriatic skin lesions and 8 patients (7.77%) developed skin and joint complaints simultaneously. 19 patients were not assessed.

**Comorbidities:**

| Parameter                          | Psoriasis, n (%) | Psoriatic arthritis, n (%) | Other rheumatological diseases, n (%) | P-value* |
|------------------------------------|------------------|----------------------------|--------------------------------------|----------|
| Number, n in total                 | 120 (100)        | 103 (100)                  | 42 (100)                             |          |
| Infectious diseases                | 9 (7.50)         | 6 (5.83)                   | 5 (11.90)                            | 0.4684 ‡ |
| Malignancies                       | 16 (13.33)       | 16 (15.53)                 | 7 (16.67)                            | 0.8332 † |
| Cardiovascular diseases            | 45 (37.50)       | 31 (30.10)                 | 20 (47.62)                           | 0.1275 † |
| Pulmonary diseases                 | 13 (10.83)       | 11 (10.68)                 | 8 (19.05)                            | 0.3188 † |
| Diabetes mellitus                  | 15 (12.50)       | 13 (12.62)                 | 6 (14.29)                            | 0.9534 † |
| Peripheral vascular diseases       | 12 (10.00)       | 5 (4.85)                   | 11 (26.19)                           | 0.0015 ‡ |
| Gastrointestinal diseases          | 31 (25.83)       | 28 (27.18)                 | 13 (30.95)                           | 0.8138 † |
| Ophthalmological diseases          | 3 (2.50)         | 3 (2.91)                   | 5 (11.90)                            | 0.0392 ‡ |
| Neurological and psychiatric       | 20 (16.67)       | 36 (34.95)                 | 12 (28.57)                           | 0.0070 † |

*P-values are given for Chi-Square Test (†) and Fishers-Exact-Test (‡).

Abbreviations: n: number

The prevalence of comorbidities was high in all groups, especially, concerning cardiovascular, gastrointestinal and neurological/psychiatric diseases. Cardiovascular diseases were the most commonly observed comorbidity while ophthalmological diseases were the least common observed comorbidity. Significant differences were observed in the prevalence for peripheral vascular (p = 0.0015), ophthalmological (p = 0.0392) and neurological/psychiatric diseases (p = 0.0070) (Table 4). Pair-by-pair
analysis lead to significant differences between PsA and other rheumatological diseases as well as between psoriasis and other rheumatological diseases regarding vascular and ophthalmological diseases (PsA vs. other rheumatological diseases: vascular: p = 0.0005541, ophthalmological p = 0.04543; psoriasis vs. other rheumatological diseases: vascular p = 0.01978, ophthalmological p = 0.02834). Moreover, we also noticed significant differences in neurological/psychiatric diseases between psoriasis and PsA group (p = 0.002843).

Other-rheumatological diseases:

In total, rheumatological diseases other than PsA were observed in 43 patients. The most common diagnoses were connective tissue diseases (20 patients), rheumatoid arthritis (12 patients) and gout (8 patients). Small vessel vasculitis, reactive arthritis, and axial spondyloarthritis were all diagnosed once, and undifferentiated mono- or oligoarthritis twice. A rheumatic disorder other than PsA was first diagnosed in 26 patients, with a mean age of 53.7 (± 17.7) years. Three patients in whom initially PsA was suspected, were diagnosed with rheumatoid arthritis. In 35 patients (9.38%), the rheumatologist confirmed the suspected diagnosis of the treating dermatologist.

Non-rheumatological diseases:

67 out of 373 patients (17.96%) were diagnosed with a non-rheumatological condition. Osteoarthritis was diagnosed most frequently in 57 patients (85.1%). In 43 patients out of these 57 patients (75.44%), initial suspicion of PsA by dermatologist was later diagnosed as OA. Of these 57 patients with OA, 50 patients were initially diagnosed with OA, 6 in period 1 and 44 in period 2. Some patients received multiple diagnoses while somatic symptom disorder was diagnosed seven times. Two patients each with pain from overstrain and Raynaud's phenomena and one each with tendinopathy and enthesopathy were recorded.

Symptoms and signs of psoriatic arthritis and osteoarthritis:
Table 5
Reported symptoms and signs of patients with psoriatic arthritis and osteoarthritis

| Element                                      | Psoriatic arthritis, n (%) | Osteoarthritis, n (%) | P-value* |
|----------------------------------------------|-----------------------------|-----------------------|----------|
| **Reported symptoms**                        |                             |                       |          |
| Number, n in total                           | 103 (100)                   | 55 (100)              |          |
| Arthralgia                                   | 103 (100)                   | 52 (94.55)            | 0.0407 ‡ |
| Morning stiffness of digits                  | 29 (28.16)                  | 7 (12.73)             | 0.0451 † |
| Swollen joints                               | 56 (54.37)                  | 18 (32.73)            | 0.0151 † |
| Tender joints                                | 26 (25.24)                  | 6 (10.91)             | 0.0539 † |
| Pain insomnia                                | 13 (12.62)                  | 6 (10.91)             | 0.9533 † |
| Alleviation with movement                    | 4 (3.88)                    | 2 (3.64)              | 1.0000 ‡ |
| **Clinical signs**                           |                             |                       |          |
| Number, n in total                           | 26 (25.24)                  | 1 (1.82)              | <0.0001 ‡|
| Joint deformities                            | 3 (2.91)                    | 1 (1.82)              | 1.0000 ‡ |
| Positive Gaenslen's Squeeze Test of MCP joints| 8 (7.77)                    | 0 (0)                 | 0.0512 ‡ |
| Enthesitis                                   | 3 (2.91)                    | 0 (0)                 | 0.5520 ‡ |
| Dactylitis                                   | 12 (11.65)                  | 0 (0)                 | 0.0086 ‡ |

* P-values are given for Chi-Square Test (†) and Fishers-Exact-Test (‡).

Abbreviations: n: number, MCP: metacarpophalangeal

All patients with PsA (100%) and nearly all with OA (95%) reported of arthralgia, while swollen joints were observed in 54% patients in PsA and 33% patients in OA. Tender joints were presented in 25% cases in PsA and 11% cases in OA. In OA patients, no enthesitis or dactylitis was observed in contrast to PsA. Significant differences were detected in arthralgia (p = 0.0407), swollen joints (p = 0.0151), morning stiffness of the digitis (p = 0.0451) and dactylitis (p = 0.0086) (Table 5).

**Patient journey before and after the foundation of a psoriatic arthritis center:**

A number of 372 consultations were assessed over both periods, 52 in period 1 (14 %) and 320 in period 2 (86 %). Despite the fact that 6-fold increase in consultation was reported in period 2, the distribution of consultation type (day patient vs. inpatient vs. outpatient) was altered. The outpatient clinic played the greatest role in period 2 (139 consultations, 43 %) while it played the subordinated role in period 1 (7 consultations, 13 %).
During this period, 103 patients were diagnosed with PsA in total, out of which 15 were consulted in period 1, while 88 in period 2. These patients suffered from rheumatological complaints for 36 (IQR:10–108) median months in total, 36.0 (IQR:10.0-126.0) median months in period 1 and 24.0 (IQR:6.0–60.0) median months in period 2. No significant difference was observed (p = 0.1527) using the Wilcoxon test but a trend for shortened duration of about 12 months was noted making it clinically relevant (Fig. 1).

Period 1: prior foundation of psoriatic arthritis center, period 2: after foundation of psoriatic arthritis center, duration of rheumatological complaints in moths until presentation at the Department of Dermatology, days to rheumatological consultation, assessed median/mean differences, respective diagnoses made.

Overall, 209 patients out of all assessed patients (373) complained about skin manifestations before the begin of arthralgia, 43 patients reported arthralgia before skin manifestations and 30 developed skin lesions simultaneously to joint complaints. Data on analysis of both periods showed the need of less median months (180 (IQR:84–360)) in period 2 compared to period 1 (204 (IQR:60–336)) to report the beginning of skin lesions until joint complaints occurred. Developing joint complaints before skin manifestation took 84 (IQR:44–96) median months in period 1 and 21 (IQR:5.8–28.5) median months in period 2.

In PsA, 69 patients complained about skin lesions before the begin of arthralgia, seven patients reported of arthralgia before the onset of skin lesions and 8 developed psoriatic skin lesions simultaneously to joint complaints. Focusing on both analyzed studied periods, in period 1 it took 288 (IQR: 153.0–438.0) median months and in period 2 264 (IQR: 120.0–360.0) median months from the onset of skin lesions until joint complaints occurred. Developing joint complaints before onset of skin lesions it took 48.0 (IQR: 25.0–85.0) median months in period 2.

During both periods, in 78 out of 277 cases, suspected PsA was confirmed and diagnosis was revised in 73 cases, rheumatological disease was revised in eight cases and non-rheumatological disease was diagnosed in 48 cases. The remaining 70 cases persisted as suspected diagnoses. In period 1, PsA was diagnosed in 10 out of 32 patients (31.25%) with suspected PsA, and in period 2, 68 out of 245 patients (27.8%) with suspected PsA were diagnosed with PsA.

In period 1, one of two patients who was first diagnosed with PsA fulfilled the CASPAR classification criteria whereas in period 2 all 41 PsA patients fulfilled respective classification criteria. Concerning first diagnosis of other rheumatological diseases, in period 1, 1 patient (10%) fulfilled the classification criteria for rheumatoid arthritis (11). In period 2, 22 patients (95.65%) met the respective criteria. Using the Chi-Square Test for meeting PsA classification criteria (p = 0.03458) and the Fishers-Exact-Test for meeting classification criteria for other rheumatological diseases (p = 0.0001) over both periods, significant differences were observed.
Discussion

To date, very few studies have evaluated the feasibility of setting up a specialized PsA center. In fact, this kind of structure with very close cooperation of dermatologists and rheumatologists is limited mostly to university hospitals. The aim of our PsA center is to optimize the medical care with a team-oriented approach, not only focusing on PsA, but also other rheumatological diseases, which might present with skin abnormalities.

The direct referral of patients with suspected PsA or other rheumatological diseases to the PsA center can help to overcome the confusion between arthritis diagnosis and treatment in patients, thus increasing the attention of patients to management and follow-up in this specialized center. The PsA center’s most critical priorities are the early diagnosis and treatment of PsA and other rheumatological diseases. PsA, if left untreated, can result in irreversible joint deformity causing immobility and worsening the overall well-being issues (12).

Differential diagnosis is sometimes complex and early management is difficult, requiring the aid of a rheumatologist. There are many studies underlying the delay in diagnosis and treatment of PsA, which typically leads to different orthopedic operations until these patients finally are diagnosed (12, 13). Previous studies also suggested, that there are significant deviations in clinical management and follow-up of patients with psoriasis and PsA, depending on the specialist they initially choose to see, often leading to misdiagnosis and sometimes loss of diagnosis, decreasing the compliance of the patient (14–16). In addition, in a specialized PsA center, rheumatologists are acquainted with topical therapies used in dermatology as well as with the dermatological view of systemic therapies concerning the efficacy in plaque psoriasis. In the PsA center, severity of skin changes are carefully assessed by the dermatologist and reported to the rheumatologist, so that both can decide on a common therapeutic algorithm, tailored for each patient. Furthermore, we can learn more about paradoxical reactions on the skin due to different biological therapies, which could be addressed in an interdisciplinary setting.

In this study, psoriasis and PsA were the most commonly observed diseases. A positive family history for psoriasis was present in 37.86% of patients with PsA. Although, patients with PsA are usually negative for rheumatoid factor, elevated levels were found in 6 cases (5.83%) (17). A similar percentage was observed in patients with psoriasis and non-rheumatological disorders, probably relating to similar presence in the general population (18).

Our data did not show significant differences in PASI, DLQI, GEPARD and CASPAR scores between patients with psoriasis (without PsA) and PsA. The GEPARD questionnaire (mean ± SD: Psoriasis = 6.7 (± 3.3), PsA = 8.2 (± 2.7)) and the CASPAR classification criteria (mean ± SD: Psoriasis = 5.1 (± 1.8), PsA = 5.8 (± 1.7)) which are commonly used, were not found to be helpful for differentiating between psoriasis and PsA. This is commonly observed in clinical practice, although the literature suggests a better diagnostic yield (19, 20). Despite this, the higher level of DLQI in patients with PsA, which primarily affects the impact of the skin symptoms on health-related quality of life, indicated a greater degree of impairment in
those patients (21). On the other hand, the dermatologist should not stop asking for joint complaints in psoriasis patients as PsA is often developed in the later history of psoriasis (4).

Plaques psoriasis (86.41%) was the most common type of psoriasis in PsA patients. Current literature underlines our observation, as a 2-3-fold higher risk of developing PsA in patients with scalp lesions, nail dystrophy and perianal lesions is described (22). Our patients with PsA reported scalp involvement in 49.51%, rima ani involvement in 48.54% and nail involvement in 42.72%, so no specific form of psoriasis was found to be linked to PsA.

Our study yielded a similar increase in prevalence of comorbidities as published, highlighting cardiovascular diseases, gastrointestinal, psychiatric and neurological diseases in psoriasis and PsA (23).

A total of 43 patients out of 373 (11.5%) were diagnosed with another rheumatological disease than PsA, underlining the significance of the dermatological-rheumatological approach not only in PsA.

Non-rheumatological diseases were diagnosed in 67 patients out of 373 (18%). In 57 patients osteoarthritis (OA) was diagnosed. Osteoarthritis was diagnosed in 43 patients with initially suspicion of PsA. This underlines the complexity of differentiating OA from PsA for dermatologist. Although, we assessed significant differences in the history of arthralgia (p:0.0407), swollen joints (p:0.0151), morning stiffness of the digits (p:0.0451) and dactylitis (p:0.0086) tender joints and pain insomnia did not play prominent roles. These symptoms and clinical signs can help to distinguish between OA and PsA but further diagnostics is required. This emphasizes the difficulty for dermatologists in interpreting joint complaints and that is not described in the literature. Future trials will need to focus more on diagnostic tools such as ultrasound, facilitating the diagnosis of arthritis. An additional validated questionnaire could be another future vision improving the diagnostic yield, but is obviously quite complex, as shown by our results concerning CASPAR classifications criteria and the GEPPARD questionnaire.

Data on patient journey in both the periods show that the time taken for diagnosis by the rheumatologist was about 12 months shorter in period 2 compared to period 1, which is clinically significant, in order to prevent irreversible damage of the joint.

There are several examples of collaboration between different departments such as uveitis clinics or reproduction and pregnancy clinics in which the patient is seen by various experts for chronic medical complaints (21, 24, 25). These experiences demonstrate a significant diagnostic and therapeutic benefit. Positive aspects of these specialized centers include avoiding excessive laboratory testing, minimizing the number of visits, efficient decision-making and efficient flow of knowledge leading to fastened diagnosis and procedures for patient management.

Dermatologists and rheumatologists mutually are involved in the management of all overlapping disorders as they specifically focus on their area of expertise. They see the patients in their respective offices at different times. This form of practice model resulted in the lack of communication and
teamwork between specialists (26). Our practice model not only decreased the duration of rheumatological complaints until request in period 2 but also significantly reduced the days required from consultation request until the consultation. In period 2, patients were seen in average 9 days earlier by the rheumatologist. Although, not investigated in this trial, it is imaginable, that the interdisciplinary consultation is not as time consuming as the single visits of each physician.

The limitations of the study are in regards to the retrospective and the monocentric study design. Future prospective studies are necessary in order to confirm our observations.

One of the greatest benefits of the PsA center is also the inspiration for research provided by the collaboration of both dermatologists and rheumatologists.

is, to the best of our knowledge, the first joint, dual center for both psoriasis, psoriatic arthritis and patients with other rheumatological diseases. Our conclusions complement the findings of other research groups worldwide. The importance of service delivery in teams is illustrated by our data in the taking control of complicated or complex patients, suffering from more than one disease into account.

Conclusions

The results of our study confirm the importance of a multidisciplinary university dermatology-rheumatology management in a specialized PsA center. Time to rheumatological examination and time to diagnosis was significantly decreased. These data form the concept of a model that can enhance medical treatment through close interdisciplinary cooperation, which should be implemented nationally and globally. Further research showing the value of such a centered care in greater patient numbers is obligatory.

Abbreviations

Anti-CCP antibody - Anti-cyclic citrullinated peptide antibody
BMI - Body mass index
CASPAR - Classification Criteria for Psoriatic Arthritis
CRP - C-reactive protein
DLQI - Dermatology Life Quality Index
GEPARD - German Psoriatic Arthritis Diagnostic Questionnaire
IQR – Interquartile range
MCP – Metacarpophalangeal
N - Number
OA - Osteoarthritis
PASI - Psoriasis Area and Severity Index
PsA - Psoriatic arthritis
RF - Rheumatoid factor
SD - Standard deviation

Declarations

Ethics approval, accordance and consent to participate:

The study followed the principles of the Declaration of Helsinki and the guidelines of Good Clinical Practice and was approved by the local ethics committee of the University Hospital of Bonn (Ethik-Kommission der Medizinischen Fakultät Bonn – Lfd. Nr. 100/20). Due to the retrospective design of the study, the need for informed consent was waived by the ethics committee of the University Hospital of Bonn, Germany, (Chairman Prof. Dr. Racké).

Consent for publication:

All authors attest to the validity of the data and give consent to their publication.

Availability of data and materials:

The data used and/or analyzed during the current study are included in this published article. Additional data are available from the corresponding author on reasonable request.

Competing interests:

The authors declare that they have no competing interests.

Funding:

This work was supported by financial funding from Novartis. The funding sources had no role in the study design, data collection, analysis, interpretation of data, manuscript writing, or decision to submit.

Author’s contributions:

JZ, DWT, VSS conceived and prepared the study protocol and the database; JZ reviewed the patients’ records and gathered the relevant data; JZ and CB analyzed the data; JZ, DWT, VSS wrote the draft of the manuscript; all authors reviewed the draft and contributed to the final version of the manuscript.
Acknowledgements:
none

Author’s information:
Information on title page

References

1. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, et al. Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study. Dermatology. 2006;212(2):137–44.

2. Haberman R, Perez-Chada LM, Merola JF, Scher J, Ogdie A, Reddy SM. Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics. Curr Rheumatol Rep. 2018 Dec;20(12):76.

3. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009 May;160(5):1040–7.

4. Christophers E, Barker J, Griffiths C, Daudén E, Milligan G, Molta C, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010 May;24(5):548–54.

5. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013 May;72(5):736–40.

6. Velez NF, Wei-Passanese EX, Husni ME, Mody EA, Qureshi AA. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Arch Dermatol Res. 2012 Jan;304(1):7–13.

7. Gottlieb AB, Mease PJ, Mark Jackson J, Eisen D, Amy Xia H, Asare C, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. J Dermatol Treat. 2006 Jan;17(5):279–87.

8. Chang CA, Gottlieb AB, Lizzul PF. Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol. 2011 Oct;7(10):588–98.

9. Ghosh A, Kole A. Cutaneous manifestations of systemic lupus erythematosus in a tertiary referral center. Indian J Dermatol. 2009;54(2):132.

10. R Core Team. R: A language and environment for statistical computing. R Found Stat Comput Vienna Austria. 2020;

11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569–81.

12. Strauss EJ, Alfonso D, Baidwan G, Di Cesare PE. Orthopedic manifestations and management of psoriatic arthritis. Am J Orthop Belle Mead NJ. 2008 Mar;37(3):138–47.
13. Nystad TW, Husum YS, Furnes ON, Fevang B-TS. Incidence and Predictive Factors for Orthopedic Surgery in Patients with Psoriatic Arthritis. J Rheumatol. 2018 Nov;45(11):1532–40.

14. Cobo-Ibáñez T, Villaverde V, Seoane-Mato D, Muñoz-Fernández S, Guerra M, del Campo PD, et al. Multidisciplinary dermatology–rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review. Rheumatol Int. 2016 Feb 1;36(2):221–9.

15. Luchetti MM, Benfaremo D, Campanati A, Molinelli E, Ciferri M, Cataldi S, et al. Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic. Clin Rheumatol. 2018 Oct;37(10):2741–9.

16. Yélamos O, Ros S, Puig L. Improving patient outcomes in psoriasis: strategies to ensure treatment adherence. Psoriasis Auckl NZ. 2015;5:109–15.

17. Zachariae H. Prevalence of Joint Disease in Patients with Psoriasis: Implications for Therapy. Am J Clin Dermatol. 2003;4(7):441–7.

18. Simard JF, Holmqvist M. Rheumatoid factor positivity in the general population. BMJ. 2012 Sep 6;345(sep06 2):e5841–e5841.

19. Härle P, Letscher K, Wittig B, Mrowietz U. Sensitivity of the GEPARD Patient Questionnaire to Identify Psoriatic Arthritis in Patients with Psoriasis in Daily Practice: The GEPARD-Life Study. Dermatology. 2016;232(5):597–605.

20. Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHUGH J, et al. The CLASsification for Psoriatic ARthritis (CASPAR) Criteria – A Retrospective Feasibility, Sensitivity, and Specificity Study: Table 1. J Rheumatol. 2012 Jan;39(1):154–6.

21. Theodorakopoulou E, Dalamaga M, Katsimbri P, Boumpas DT, Papadavid E. How does the joint dermatology–rheumatology clinic benefit both patients and dermatologists? Dermatol Ther [Internet]. 2020 May [cited 2020 Nov 1];33(3). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.13283

22. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study. Arthritis Rheum. 2009 Feb 15;61(2):233–9.

23. Tobin A-M, Veale DJ, Fitzgerald O, Rogers S, Collins P, O'Shea D, et al. Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis. J Rheumatol. 2010 Jul;37(7):1386–94.

24. Muñoz-Fernández S, Martín-Mola E. Uveitis. Best Pract Res Clin Rheumatol. 2006 Jun;20(3):487–505.

25. Wiles KS, Bramham K, Vais A, Harding KR, Chowdhury P, Taylor CJ, et al. Pre-pregnancy counselling for women with chronic kidney disease: a retrospective analysis of nine years’ experience. BMC Nephrol. 2015 Dec;16(1):28.

26. Soleymani T, Reddy SM, Cohen JM, Neimann AL. Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology–Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients. Curr Rheumatol Rep. 2018 Jan;20(1):1.
Figures

![Dermatological-Rheumatological patient journey](image)

**Figure 1**

Dermatological-Rheumatological patient journey over both periods

| Department of Dermatology | Period 1 | Period 2 |
|---------------------------|----------|----------|
| Duration of rheumatological complaints in months, median (IQR) | 36.0 (10.0–126.0) | 24.0 (6.0–60.0) |

| Consultation | Days to rheumatological consultation, mean (± SD) |
|--------------|-----------------------------------------------|
|              | 19.5 (±31.6) | 10.2 (±16.4) |

| Diagnosis | n | Psoriatic Arthritis | Other rheumatological diseases | Non-rheumatological diseases |
|-----------|---|---------------------|------------------------------|-------------------------------|
| n = 103   |   |                     |                              |                               |
| n = 43    |   |                     |                              |                               |
| n = 67    |   |                     |                              |                               |

Median/Mean Difference

- Duration: 12 months
- Days: 9 days